Clinical trials
Phase 2 Dermatomyositis trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2006 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2018 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Recruiting | 5 |
| Terminated | 5 |
| Active, not recruiting | 2 |
| Withdrawn | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 4 |
| Novartis Pharmaceuticals | 3 |
| Kezar Life Sciences, Inc. | 2 |
| Pfizer | 2 |
| Alison Ehrlich | 1 |
| Chester Oddis | 1 |
| Corbus Pharmaceuticals Inc. | 1 |
| EMD Serono Research & Development Institute, Inc. | 1 |
| Idera Pharmaceuticals, Inc. | 1 |
| Lakefront Biotherapeutics NV | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Dermatomyositis | 31 |
| Polymyositis | 11 |
| Myositis | 10 |
| Arthritis, Juvenile | 2 |
| Arthritis, Rheumatoid | 2 |
| Calcinosis | 2 |
| Lung Diseases, Interstitial | 2 |
| Lupus Erythematosus, Systemic | 2 |
| Muscle Weakness | 2 |
| Muscular Diseases | 2 |
Trials
Showing 1 to 25 of 31. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.